cor2ed
engage checkpoint medical linkedin twitter
bg

The Role of PARP Inhibition in Clinical Practice

The Role of PARP Inhibition in Clinical Practice

Prof. Jonathan A. Ledermann, Dr. Rebecca Dent, Dr. Robert L. Coleman, Prof. Eric Pujade-Lauraine

Accredited e-learning: The Role of PARP inhibition in Clinical Practice
Portrait of Jonathan A. Ledermann
Prof. Jonathan A. Ledermann

Medical Oncologist

UCL Cancer Institute

United Kingdom (UK)

Portrait of Rebecca Dent
Dr. Rebecca Dent

Medical Oncologist

National Cancer Center Singapore

Singapore

Portrait of Robert L. Coleman
Dr. Robert L. Coleman

Gynaecologic Oncologist

US Oncology Research

United States (US)

Portrait of Eric Pujade-Lauraine
Prof. Eric Pujade-Lauraine

Gynaecologic Oncologist

Hôpital Hôtel-Dieu

France

preview next

time E-learning | open 60 min |accreditation: EACCME

download resources

THERE ARE NO DOWNLOADS FOR THIS PROGRAMME

I agree that this educational programme:

Was valuable to me:

1/3

DNA Damage Response (DDR) and PARP inhibitors are promising but complex therapeutic strategies.

Understand why, where and how PARP inhibitors work in clinical practice, and look into the future of targeting DDR with this interactive free to access e-learning course. Designed to support you in selecting the appropriate treatment strategy with PARP inhibitors in the appropriate patient population and to provide the best possible patient care.

This course is endorsed by the Innovative Breast Cancer Research Group (SOLTI), the Gynecological Cancer Group Singapore (GCGS) and the Gynecologic Oncology Trial and Investigation Consortium (GOTIC).

Downloadable slides accompany this e-learning for your own use.

 

Other programmes of interest

Other programmes developed by Prof. Jonathan A. Ledermann

Other programmes developed by Dr. Rebecca Dent

Other programmes developed by Prof. Eric Pujade-Lauraine